Proposal for a new protein therapeutic immunogenicity titer assay cutpoint

Bioanalysis

Volumn 3, Issue 23, 2011, Pages 2627-2636

  Wakshull, Eric ^a   Hendricks, Robert ^a   Amaya, Caroline ^a   Coleman, Daniel ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; IMMUNOASSAY; IMMUNOGENICITY; INTERMETHOD COMPARISON; PLOTS AND CURVES; REFERENCE VALUE; SCREENING TEST; STATISTICAL ANALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; IMMUNOGENETIC PROCESSES; IMMUNOLOGIC TECHNIQUES; IMMUNOLOGIC TESTS; MODELS, IMMUNOLOGICAL; PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 82955239926     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.273     Document Type: Article

References (9)

1. Mire-Sluis AR, Chen YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004). (Pubitemid 38900899)
2. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. BioPharm. Int. Parts 1-3, Nov, Dec 2004, Jan 2005.
3. Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualifcation of cell-based assays used for the detection of neutralizing antibody responses elicted to biological therapeutics. J. Immunol. Methods 321(1-2), 1-18 (2007). (Pubitemid 46454303)
4. Koren E, Smith H, Shores E et al. Recommendations on risk-based strategies for detecion and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008).
5. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for the detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2009).
6. Ponce R, Abad L, Amaravadi L et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54(2), 164-182 (2009).
7. EMA. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (EMEA/CHMP/BMWP/14327/2006), effective April 2008.
8. Wakshull E, Coleman D. Confrmatory immunogenicity assays. In: Detection and Quantifcation of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey M (Ed.). John Wiley & Sons Inc., New York, USA (2011) (In Press).
9. Qiu ZJ, Ying Y, Fox M et al. A novel homogenous biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum. J. Immunol. Methods 362(1-2), 101-111 (2010).